SARS-CoV-2 Testing for Asymptomatic Patients with Cancer Prior and during Treatment: A Single Centre Experience.
Journal
Current oncology (Toronto, Ont.)
ISSN: 1718-7729
Titre abrégé: Curr Oncol
Pays: Switzerland
ID NLM: 9502503
Informations de publication
Date de publication:
06 01 2021
06 01 2021
Historique:
received:
07
10
2020
revised:
22
12
2020
accepted:
22
12
2020
entrez:
9
1
2021
pubmed:
10
1
2021
medline:
16
1
2021
Statut:
epublish
Résumé
Patients with cancer are more vulnerable to severe COVID-19. As a result, routine SARS-CoV-2 testing of asymptomatic patients with cancer is recommended prior to treatment. However, there is limited evidence of its clinical usefulness. The objective of this study is to evaluate the value of routine testing of asymptomatic patients with cancer. Asymptomatic patients with cancer attending Odette Cancer Centre (Toronto, ON, Canada) were tested for SARS-CoV-2 prior to and during treatment cycles. Results were compared to positivity rates of SARS-CoV-2 locally and provincially. All 890 asymptomatic patients tested negative. Positivity rates in the province were 1.5%, in hospital were 1.0%, and among OCC's symptomatic cancer patients were 0% over the study period. Given our findings and the low SARS-CoV-2 community positivity rates, we recommend a dynamic testing model of asymptomatic patients that triggers testing during increasing community positivity rates of SARS-CoV-2.
Identifiants
pubmed: 33419159
pii: curroncol28010032
doi: 10.3390/curroncol28010032
pmc: PMC7903264
doi:
Types de publication
Journal Article
Langues
eng
Sous-ensembles de citation
IM
Pagination
278-282Références
Oncologist. 2020 Jun;25(6):e936-e945
pubmed: 32243668
Cancer Discov. 2020 Jun;10(6):783-791
pubmed: 32345594
JAMA Oncol. 2020 Oct 1;6(10):1627-1628
pubmed: 32459297
Ann Intern Med. 2020 Jun 2;172(11):756-758
pubmed: 32219410
PLoS One. 2017 Jul 14;12(7):e0180888
pubmed: 28708843
Science. 2020 May 22;368(6493):860-868
pubmed: 32291278
Am J Epidemiol. 2018 May 1;187(5):1040-1050
pubmed: 29053783
Lancet Oncol. 2020 Mar;21(3):335-337
pubmed: 32066541